Omeros drug's pass-through status reinstated
March 22, 2018 at 17:48 PM EDT
The government spending bill reinstated the pass-through status of Omeros Corp.'s (Nasdaq: OMER) cataract surgery drug Omidria sending the stock price soaring $4.11 to close at $15.75.
